Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024
Eupraxia Pharmaceuticals announced that it will present data from its Phase 2 SPRINGBOARD study on EP-104IAR, a treatment for knee osteoarthritis, at the EULAR European Congress of Rheumatology 2024 in Vienna, Austria. The study assesses the efficacy of a long-acting fluticasone propionate intra-articular injection compared to a vehicle placebo. The presentation, under programme number OP0274, will occur on June 14, 2024, from 10:50 AM to 11:00 AM CEST. Further details will be available on the company's website.
- Presentation of Phase 2 data at a major international conference indicates progress in clinical development.
- Focus on a significant unmet medical need in knee osteoarthritis.
- Utilization of proprietary DiffuSphere™ technology suggests innovation in drug delivery.
- Exposure at EULAR could enhance visibility and credibility among healthcare professionals.
- No mention of Phase 2 study results in the press release, leaving efficacy and safety data unclear.
- Potential for negative market reaction if presented data is not compelling.
- Costs associated with international presentations and continued clinical trials may impact financials.
- Delay in commercializing EP-104IAR if further studies are required.
VICTORIA, BC, June 5, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that results from its Phase 2 study of EP-104IAR for the treatment of osteoarthritis of the knee will be presented at the upcoming European Alliance of Associations for Rheumatology ("EULAR") European Congress of Rheumatology 2024 (the "Meeting"). The EULAR Meeting is being held in
Presentation Details: | |
Programme No.: | OP0274 |
Presentation Title: | Efficacy of a Long-Acting Fluticasone Propionate Intra-Articular Injection (EP-104IAR) in Knee Osteoarthritis: Per-Protocol Analysis of a Randomised, Double-Blind, Phase 2 Trial of EP-104IAR vs Vehicle Placebo (SPRINGBOARD) |
Session Type: | Oral Abstract Presentation |
Session Title: | New Developments in Osteoarthritis |
Session Date & Time: | June 14, 2024, from 10:50 AM to 11:00 AM CEST |
The presentation will also be available on Eupraxia's website at:
https://eupraxiapharma.com/our-science/clinical-trials-and-publications/default.aspx.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. The Company strives to provide improved patient benefit and has developed technology designed to deliver targeted, long-lasting activity with fewer side effects. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tuneable pharmacokinetic (PK) profiles. This investigational technology can be engineered for use with multiple active pharmaceutical ingredients and delivery methods.
Eupraxia recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to osteoarthritis of the knee. The trial met its primary endpoint and three of the four secondary endpoints. Eupraxia has expanded the EP-104 platform into gastrointestinal disease with the Phase 1b/2a RESOLVE trial for treating eosinophilic esophagitis. Eupraxia is also developing a pipeline of later- and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: www.eupraxiapharma.com.
This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "suggests", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", "potential" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward looking statements in this news release include statements regarding the details of the Company's presentations at the upcoming EULAR Meeting; the Company's product candidates, including expected benefits to patients with respect to safety, efficacy, duration and tolerability; the results gathered from studies and trials of Eupraxia's product candidates; the potential for the Company's technology to impact the drug delivery process; and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of our product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its products and services; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.
View original content:SOURCE Eupraxia Pharmaceuticals Inc.
FAQ
What is the SPRINGBOARD study presented by Eupraxia Pharmaceuticals?
When and where will Eupraxia present their Phase 2 study data?
What is EP-104IAR?
What technology does Eupraxia Pharmaceuticals use for their drug delivery?
Where can I find more information about Eupraxia's clinical trials?
